1. Home
  2. News
  3. Neuren Pharmaceuticals Limited
  4. New patent issued to 2032 for Neurens trofinetide in Canada
More Neuren Pharmaceuticals Limited news
Neuren Pharmaceuticals LimitedASX: NEU

New patent issued to 2032 for Neurens trofinetide in Canada

Apr 28, 2021 at 11:26 PM EDT · Issued by Neuren Pharmaceuticals Limited

Filed with ASX · Apr 28, 2021 at 11:26 PM EDT · 2 pages · English

On 6ix: 6ix.com/news/new-patent-issued-to-2032-for-neurens-trofinetide-in-canada

Neuren Pharmaceuticals Limited on 6ix

Story so far

  • Successful Phase 1 trial for Neurens NNZ-2591Feb 15, 2021
  • Patent to 2034 granted in Europe for Neurens NNZ-2591Dec 3, 2019
  • Neurens Rett syndrome Phase 2 trial published in NeurologyMar 28, 2019

Earlier from Neuren Pharmaceuticals

  • Quarterly report and cash flow statement for Q1 2021Apr 22, 2021
  • S&P DJI Announces March 2021 Quarterly RebalanceMar 12, 2021
  • Neuren successfully completes manufacturing for Phase 2Mar 9, 2021
  • Neuren approaching transforming milestones in 2021Feb 23, 2021
  • Preliminary Final Report and 2020 full year accountsFeb 23, 2021

Later from Neuren Pharmaceuticals

  • Positive FDA meetings enable INDs for three Phase 2 trialsMay 31, 2021
  • Q2 2021 quarterly activity and cash flow reportJul 30, 2021
  • Phase 3 enrolment successfully completed, results in Q4 2021Aug 4, 2021
  • R&D Tax Incentive Advance Overseas Finding ApprovalAug 30, 2021
  • Angelman IND and Ethics applications submitted for NNZ-2591Aug 31, 2021
All Neuren Pharmaceuticals news releases↗

Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.

Follow Neuren Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer